Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
4D Molecular Therapeutics, Inc.FDMT-3.9221.300.720.95-24.06%-10.69%71.42(not set)$25.9924,474$7.79

Detail of 4D Molecular Therapeutics, Inc.

 
CEO
Dr. David H. Kirn M.D.
Employees
147
Industry
Biotechnology
Sector
Healthcare
Market cap
$431M

Company details

4D Molecular Therapeutics Inc. is a biotechnology company focused on developing gene therapy products for treating severe genetic diseases. The primary function of 4D Molecular Therapeutics is to design and create advanced therapies that promise to cure or significantly alter the trajectory of genetic disorders. Utilizing their proprietary Therapeutic Vector Evolution platform, the company engineers precision-guided therapies aimed at optimizing safety and efficacy. This innovative approach impacts several medical conditions across multiple organ systems, positioning the company as a frontrunner in the treatment of ophthalmology, cardiology, and pulmonology-related diseases. Headquartered in Emeryville, California, 4D Molecular Therapeutics collaborates with leading academic and commercial institutions globally, enhancing its standing through strategic partnerships and research initiatives. In the financial market, 4D Molecular Therapeutics Inc. represents an entity at the intersection of cutting-edge science and transformative healthcare solutions, drawing interest from investors who focus on companies with robust potential for growth and innovation in the biopharmaceutical sector.

Revenue
Revenue (Rev)
$17,000.00
4D Molecular Therapeutics, Inc.
FDMT • XNGS • US
$7.79
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.58
Margin profit
0.00%
52 week low
$0.00
52 week high
$0.00
50-day simple moving average
$0.00
200-day simple moving average
$0.00
Percent held by insiders
4.16%
Percent held by institutions
103.17%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
FDMT 0.00%
eps change
FDMT 0.00%